KR960010617A - Novel phenylalkylamino carbamate compounds and preparation methods thereof - Google Patents

Novel phenylalkylamino carbamate compounds and preparation methods thereof Download PDF

Info

Publication number
KR960010617A
KR960010617A KR1019940022798A KR19940022798A KR960010617A KR 960010617 A KR960010617 A KR 960010617A KR 1019940022798 A KR1019940022798 A KR 1019940022798A KR 19940022798 A KR19940022798 A KR 19940022798A KR 960010617 A KR960010617 A KR 960010617A
Authority
KR
South Korea
Prior art keywords
structural formula
following structural
represented
phenylalaninol
carbamoyl
Prior art date
Application number
KR1019940022798A
Other languages
Korean (ko)
Other versions
KR100197892B1 (en
Inventor
변재국
최용문
Original Assignee
조규향
주식회사 유공
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to KR1019940022798A priority Critical patent/KR100197892B1/en
Application filed by 조규향, 주식회사 유공 filed Critical 조규향
Priority to DE69513140T priority patent/DE69513140T2/en
Priority to CA002176012A priority patent/CA2176012C/en
Priority to PCT/KR1995/000114 priority patent/WO1996007637A1/en
Priority to RU96113126/04A priority patent/RU2104266C1/en
Priority to US08/619,657 priority patent/US5955499A/en
Priority to JP8509386A priority patent/JP2680478B2/en
Priority to AU34856/95A priority patent/AU700544B2/en
Priority to ES95931444T priority patent/ES2140703T3/en
Priority to CN95190875A priority patent/CN1069635C/en
Priority to EP95931444A priority patent/EP0728129B1/en
Publication of KR960010617A publication Critical patent/KR960010617A/en
Application granted granted Critical
Publication of KR100197892B1 publication Critical patent/KR100197892B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/20—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by nitrogen atoms not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/12—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

본 발명은 중추신경계 치료제로서 유용한 페닐알킬아미노 카바메이트 화합물과 그의 약제학적으로 유용한 염 및 그의 제조방법에 관한 것으로서, 좀 더 상세하게는 특히 항우울제 및 항불안제로서 유용한 O-카바모일 페닐알라니놀 라세미체와 그의 순수한 D- 및 L-광학이성질체, 이들의 약제학적으로 유용한 염 및 이들을 제조하는 방법에 관한 것이다.The present invention relates to a phenylalkylamino carbamate compound useful as a central nervous system therapeutic agent, a pharmaceutically useful salt thereof, and a method for preparing the same. And to pure D- and L-isomers thereof, pharmaceutically useful salts thereof, and methods of making them.

Description

신규한 페닐알킬아미노 카바메이트 화합물과 그의 제조방법Novel phenylalkylamino carbamate compounds and preparation methods thereof

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음Since this is an open matter, no full text was included.

Claims (6)

하기 구조식(Ⅰ)로 표시되는 O-카바모일-(D/L)-페닐알라니놀 화합물과 그의 약제학적으로 유용한 염.O-carbamoyl- (D / L) -phenylalaninol compounds represented by the following structural formula (I) and pharmaceutically useful salts thereof. 하기 구조식(Ⅱ)로 표시되는 O-카바모일-(D)-페닐알라니놀 화합물과 그의 약제학적으로 유용한 염.O-carbamoyl- (D) -phenylalaninol compound represented by the following structural formula (II) and its pharmaceutically useful salt. 하기 구조식(Ⅲ)으로 표시되는 O-카바모일-(D)-페닐알라니놀 화합물과 그의 약제학적으로 유용한 염.O-carbamoyl- (D) -phenylalaninol compounds represented by the following structural formula (III) and pharmaceutically useful salts thereof. 하기 구조식(Ⅳ)로 표시되는 (D/L)-페닐알라니놀을 클로로포말산 벤질에스터와 염기성 수용액하에서 반응시켜 하기 구조식(Ⅴ)로 표시되는 N-벤질옥시카보닐-(D/L)-페닐알라니놀을 합성하고, 이를 포스겐과 반응시킨 후 암모니아 수용액을 처리하여 하기 구조식(Ⅵ)로 표시되는 O-카바모일-N-벤질옥시카보닐-(D/L)-페닐알라니놀을 제조한 후, 이 (Ⅶ)화합물의 질소보호그룹인 벤질옥시카보닐을 수소화 반응에 의하여 제거하여 하기 구조식(Ⅰ)로 표시되는 O-카바모일-(D/L)-페닐알라니놀을 제조하고, 무수염산으로 에테르 용액하에서 처리하여 하기 구조식(Ⅶ)로 표시되는 O-카바모일-(D/L)-페닐알라니놀 염산염을 제조하는 것을 특징으로 하는 하기 구조식(Ⅰ)로 표시되는 O-카바모일-(D/L)-페닐알라니놀 화합물과 그의 약제학적으로 유용한 염의 제조방법.N-benzyloxycarbonyl- (D / L) represented by the following structural formula (V) by reacting (D / L) -phenylalaninol represented by the following structural formula (IV) with chloroformalic acid benzyl ester in a basic aqueous solution. -Phenylalaninol was synthesized, reacted with phosgene, and treated with aqueous ammonia solution to form O-carbamoyl-N-benzyloxycarbonyl- (D / L) -phenylalaninol represented by the following structural formula (VI): After the preparation, the benzyloxycarbonyl, which is the nitrogen protecting group of the compound (i), was removed by hydrogenation to obtain O-carbamoyl- (D / L) -phenylalaninol represented by the following structural formula (I). And O-carbamoyl- (D / L) -phenylalaninol hydrochloride represented by the following structural formula (VII) by treating with anhydrous hydrochloric acid under an ether solution to obtain the following structural formula (I) A method for preparing an O-carbamoyl- (D / L) -phenylalaninol compound and a pharmaceutically useful salt thereof. 하기 구조식(Ⅳ')로 표시되는 (D)-페닐알라니놀을 클로로포말산 벤질에스터와 염기성 수용액하에서 반응시켜 하기 구조식(Ⅴ')로 표시도는 N-벤질옥시카보닐-(D)-페닐알라니놀을 합성하고, 이를 포스겐과 반응시킨 후 암모니아 수용액으로 처리하여 하기 구조식(Ⅵ')로 표시되는 O-카바모일-(D)-페닐알라니놀을 제조한 후, 이 (Ⅵ')화합물의 질소보호그룹인 벤질옥시카보닐을 수소화 반응에 의하여 제거하여 하기 구조식(Ⅱ)로 표시되는 O-카바모일-(D)-페닐알라니놀을 제조하고, 무수염산으로 에테르 용액하에서 처리하여 하기 구조식(Ⅶ')로 표시되는 O-카바모일-(D)-페닐알라니놀 염산염을 제조하는 것을 특징으로 하는 하기 구조식(Ⅱ)로 표시되는 O-카바모일-(D)-페닐알라니놀 화합물과 그의 약제학적으로 유용한 염의 제조방법.N-benzyloxycarbonyl- (D)-represented by the following structural formula (V ') by reacting (D) -phenylalaninol represented by the following structural formula (IV') with chloroformal acid benzyl ester in a basic aqueous solution. Phenylalaninol was synthesized, reacted with phosgene, and treated with aqueous ammonia solution to prepare O-carbamoyl- (D) -phenylalaninol represented by the following structural formula (VI '), followed by (VI'). Benzyloxycarbonyl, a nitrogen protecting group of the compound, was removed by hydrogenation to prepare O-carbamoyl- (D) -phenylalaninol represented by the following structural formula (II), and treated with anhydrous hydrochloric acid under ether solution. O-carbamoyl- (D) -phenylalanine hydrochloride represented by the following structural formula (VII ') to produce O-carbamoyl- (D) -phenylal represented by the following structural formula (II) Process for the preparation of raninol compounds and pharmaceutically useful salts thereof. 하기 구조식(Ⅳ″)로 표시되는 (L)-페닐알라니놀을 클로로포말산 벤질에스터와 염기성 수용액학에서 반응시켜 하기 구조식(Ⅴ″)로 표시되는 N-벤질옥시카보닐-(L)-페닐알라니놀을 합성하고, 이를 포스겐과 반응시킨 후 암모니아 수용액으로 처리하여 하기 구조식(Ⅵ″)로 표시되는 O-카바모일-N-벤질옥시카보닐-(L)-페닐알라니놀을 제조한 후, 이 (Ⅵ″)화합물의 질소보호그룹인 벤질옥시카보닐을 수소화반응에 의하여 제거하여 하기 구조식(Ⅲ)으로 표시되는 O-카바모일-(L)-페닐알라니놀을 제조하고, 무수염산으로 에테르 용액하에서 처리하여 하기 구조식(Ⅶ″)로 표시되는 O-카바모일-(L)-페닐알라니놀 염산염을 제조하는 것을 특징으로 하는 하기 구조식(Ⅲ)으로 표시되는 O-카바모일-(L)-페닐알라니놀 화합물과 그의 약제학적으로 유용한 염의 제조방법.N-benzyloxycarbonyl- (L)-represented by the following structural formula (V ″) by reacting (L) -phenylalanineol represented by the following structural formula (IV ″) with chloroformal acid benzyl ester in basic aqueous solution. Phenylalaninol was synthesized, reacted with phosgene and treated with aqueous ammonia solution to prepare O-carbamoyl-N-benzyloxycarbonyl- (L) -phenylalaninol represented by the following structural formula (VI ″). Thereafter, benzyloxycarbonyl, a nitrogen protecting group of this (VI ″) compound, was removed by hydrogenation to prepare O-carbamoyl- (L) -phenylalanineol represented by the following structural formula (III), O-carbamoyl represented by the following structural formula (III), characterized in that O-carbamoyl- (L) -phenylalaninol hydrochloride represented by the following structural formula -(L) -phenylalanine compound and a pharmaceutically useful salt thereof. ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.※ Note: The disclosure is based on the initial application.
KR1019940022798A 1994-09-09 1994-09-09 Novel phenylalkylaminoalcohol carbamates and process for preparing the same KR100197892B1 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
KR1019940022798A KR100197892B1 (en) 1994-09-09 1994-09-09 Novel phenylalkylaminoalcohol carbamates and process for preparing the same
CA002176012A CA2176012C (en) 1994-09-09 1995-09-06 Novel phenylalkylaminoalcohol carbamates and process for preparing the same
PCT/KR1995/000114 WO1996007637A1 (en) 1994-09-09 1995-09-06 Novel phenylalkylaminoalcohol carbamates and process for preparing the same
RU96113126/04A RU2104266C1 (en) 1994-09-09 1995-09-06 Phenylalkylamino alcohols and methods of preparing thereof
DE69513140T DE69513140T2 (en) 1994-09-09 1995-09-06 NEW PHENYLALKYLAMINO ALCOHOL CARBAMATES AND A METHOD FOR THE PRODUCTION THEREOF
US08/619,657 US5955499A (en) 1994-09-09 1995-09-06 Phenylalkylaminoalcohol carbamates and process for preparing the same
JP8509386A JP2680478B2 (en) 1994-09-09 1995-09-06 Novel phenylalkylamino alcohol carbamate and method for producing the same
AU34856/95A AU700544B2 (en) 1994-09-09 1995-09-06 Novel phenylalkylaminoalcohol carbamates and process for preparing the same
ES95931444T ES2140703T3 (en) 1994-09-09 1995-09-06 NEW PHENYLALKYLAMINO-ALCOHOL CARBAMATES AND PROCESS FOR THEIR PREPARATION.
CN95190875A CN1069635C (en) 1994-09-09 1995-09-06 Novel phenylalkylaminoalcohol carbamates and process for prepn. of same
EP95931444A EP0728129B1 (en) 1994-09-09 1995-09-06 Novel phenylalkylaminoalcohol carbamates and process for preparing the same

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1019940022798A KR100197892B1 (en) 1994-09-09 1994-09-09 Novel phenylalkylaminoalcohol carbamates and process for preparing the same

Publications (2)

Publication Number Publication Date
KR960010617A true KR960010617A (en) 1996-04-20
KR100197892B1 KR100197892B1 (en) 1999-06-15

Family

ID=19392447

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019940022798A KR100197892B1 (en) 1994-09-09 1994-09-09 Novel phenylalkylaminoalcohol carbamates and process for preparing the same

Country Status (11)

Country Link
US (1) US5955499A (en)
EP (1) EP0728129B1 (en)
JP (1) JP2680478B2 (en)
KR (1) KR100197892B1 (en)
CN (1) CN1069635C (en)
AU (1) AU700544B2 (en)
CA (1) CA2176012C (en)
DE (1) DE69513140T2 (en)
ES (1) ES2140703T3 (en)
RU (1) RU2104266C1 (en)
WO (1) WO1996007637A1 (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0173862B1 (en) * 1995-02-11 1999-04-01 조규향 O-carbamoyl- (D) -phenylalaninol compounds and their pharmaceutically useful salts and methods for their preparation
US20030069630A1 (en) * 2001-03-02 2003-04-10 Robert Burgermeister Stent with radiopaque markers incorporated thereon
CA2587481A1 (en) * 2004-10-28 2006-05-11 Sk Corporation Phenylalkylamino carbamates adjunctive therapy for depression
ES2435403T3 (en) 2005-06-08 2013-12-19 Sk Biopharmaceuticals Co., Ltd. Treatment of sleep disorders and wakefulness
EP1893291B1 (en) * 2005-06-22 2010-03-03 SK Holdings Co., Ltd. Treatment of sexual dysfunction
EP2079449A2 (en) * 2006-10-13 2009-07-22 Janssen Pharmaceutica, N.V. Phenylalkylamino carbamate compositions
US8642772B2 (en) * 2008-10-14 2014-02-04 Sk Biopharmaceuticals Co., Ltd. Piperidine compounds, pharmaceutical composition comprising the same and its use
US8741950B2 (en) * 2009-06-22 2014-06-03 Sk Biopharmaceuticals Co., Ltd. Methods for treating or preventing fatigue
US8232315B2 (en) * 2009-06-26 2012-07-31 Sk Biopharmaceuticals Co., Ltd. Methods for treating drug addiction and improving addiction-related behavior
JP5836280B2 (en) * 2009-11-06 2015-12-24 エスケー バイオファーマスティカルズ カンパニー リミテッド Treatment of Attention Deficit / Hyperactivity Disorder (ADHD)
CN102781436B (en) 2009-11-06 2014-01-08 爱思开生物制药株式会社 Methods for treating fibromyalgia syndrome
US8623913B2 (en) 2010-06-30 2014-01-07 Sk Biopharmaceuticals Co., Ltd. Methods for treating restless legs syndrome
US9610274B2 (en) 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
HRP20221018T1 (en) 2013-03-13 2023-01-06 Jazz Pharmaceuticals Ireland Limited Treatment of cataplexy
KR102309836B1 (en) 2013-07-18 2021-10-12 에스케이바이오팜 주식회사 Treatment for obesity
TWI698415B (en) 2014-02-28 2020-07-11 南韓商愛思開生物製藥股份有限公司 Aminocarbonylcarbamate compounds
US10888542B2 (en) 2014-02-28 2021-01-12 Sk Biopharmaceuticals Co., Ltd. Aminocarbonylcarbamate compounds
US10195151B2 (en) * 2016-09-06 2019-02-05 Jazz Pharmaceuticals International Iii Limited Formulations of (R)-2-amino-3-phenylpropyl carbamate
CN109996540A (en) * 2016-09-06 2019-07-09 爵士制药国际Iii有限公司 (R) solvate forms of -2- amino -3- Phenylpropylamino formic acid esters
ES2964943T3 (en) 2016-10-06 2024-04-10 Axsome Malta Ltd Carbamoylphenylalaninol compounds for medical use
WO2018133703A1 (en) * 2017-01-20 2018-07-26 苏州科睿思制药有限公司 Crystal form of r228060 hydrochloride and preparation method and use thereof
AU2018278332B2 (en) 2017-06-02 2022-05-19 Jazz Pharmaceuticals Ireland Limited Methods and compositions for treating excessive sleepiness
US11413264B2 (en) 2017-07-31 2022-08-16 Jazz Pharmaceuticals Ireland Limited Carbamoyl phenylalaninol analogs and uses thereof
WO2020035769A1 (en) 2018-08-14 2020-02-20 Glenmark Pharmaceuticals Limited; Glenmark Life Sciences Limited Process for the preparation of solriamfetol and salt thereof
WO2021001457A1 (en) 2019-07-04 2021-01-07 Sandoz Ag Crystalline (r)-2-amino-3-phenylpropylcarbamate acid addition salts
US10940133B1 (en) 2020-03-19 2021-03-09 Jazz Pharmaceuticals Ireland Limited Methods of providing solriamfetol therapy to subjects with impaired renal function
IT202000013855A1 (en) 2020-06-10 2021-12-10 Flamma Spa A PROCESS FOR THE PURIFICATION OF (R)-2-AMINO-3-PHENYLPROPYL CARBAMATE
KR102390194B1 (en) 2020-08-03 2022-04-25 셀라이온바이오메드 주식회사 A composition for treating Kca3.1 channel mediated diseases comprising phenylalkyl carbamate compounds

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1434826A (en) * 1973-11-14 1976-05-05 Gallardo Antonio Sa Esters and carbamates of aminoalkanols

Also Published As

Publication number Publication date
EP0728129B1 (en) 1999-11-03
KR100197892B1 (en) 1999-06-15
JPH09503231A (en) 1997-03-31
DE69513140T2 (en) 2000-08-17
CN1069635C (en) 2001-08-15
ES2140703T3 (en) 2000-03-01
DE69513140D1 (en) 1999-12-09
AU3485695A (en) 1996-03-27
AU700544B2 (en) 1999-01-07
WO1996007637A1 (en) 1996-03-14
CA2176012C (en) 1999-01-05
CN1135209A (en) 1996-11-06
US5955499A (en) 1999-09-21
RU2104266C1 (en) 1998-02-10
CA2176012A1 (en) 1996-03-14
JP2680478B2 (en) 1997-11-19
EP0728129A1 (en) 1996-08-28

Similar Documents

Publication Publication Date Title
KR960010617A (en) Novel phenylalkylamino carbamate compounds and preparation methods thereof
KR910009712A (en) Cefem compound and preparation method thereof
KR910011891A (en) Peptide compound, preparation method thereof and pharmaceutical composition containing same
KR880003974A (en) Selective Amidation Method of Diamine
KR860007207A (en) Method for preparing phenyl carbamate and its salts
JPS59205350A (en) Carboxyalkylpeptide derivative
OA08182A (en) New peptide derivatives with a nitrogenous polycyclic structure, their method of preparation and the pharmaceutical compositions which contain them.
KR890005100A (en) Imidazopyridine Compound and its preparation
KR860006452A (en) Process for preparing piperidine compound
US4535167A (en) Chiral, N-protected, N-substituted α-amino acids
DE3677798D1 (en) AMINO ACID DERIVATIVES AND THEIR METHOD FOR THE PRODUCTION THEREOF.
EP1004583A3 (en) Process and hydantoin intermediates for the synthesis of growth hormone secretagogues
KR940014435A (en) 15-deoxyspergualin homologue, preparation method thereof and therapeutic use
ATE165810T1 (en) N-SUBSTITUTED DERIVATIVES OF N-METHYL-3-(P-TRIFLUORMETHYLPHENOXY)-3-PHENYLPROPYLAMIN AND METHOD FOR THE PRODUCTION THEREOF
KR920014777A (en) Substituted 1,2,3,4-tetrahydrocyclopent [b] indole 1,2,3,3a, 4,8a-hexahydrocyclopent [b] indole and related compounds, intermediates thereof, preparation methods and pharmaceutical agents Purpose
KR940003953A (en) 1. 4-benzodioxane derivative
EP0255807B1 (en) N-alkylamides of d-(+) -carnitine having antibacterial activity, process for their preparation and pharmaceutical and cosmetic compositions containing same
KR960022498A (en) Esculetin derivatives, preparation method thereof and pharmaceutical composition
KR910016691A (en) Novel substituted-amine compounds and preparation methods thereof
KR900011724A (en) Certain pyrrolylphenyl-substituted hydroxamic acid derivatives
PT85869A (en) Process for preparing amino acid derivative anti-convulsant
KR960029312A (en) N-arylalkylphenylacetamide derivatives and preparation methods thereof
KR950032097A (en) 15-deoxysperguarine analogs, methods for their preparation and therapeutic uses
PT86250B (en) PREPARATION PROCESS OF 2-AMINOACETAMIDE DERIVATIVES
KR920701144A (en) Amino acid derivative

Legal Events

Date Code Title Description
A201 Request for examination
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20130109

Year of fee payment: 15

FPAY Annual fee payment

Payment date: 20140212

Year of fee payment: 16

EXPY Expiration of term